EXAI Stock Overview
An artificial intelligence (AI) driven Pharma-tech company, engages in design and develop differentiated medicines for diseases with high unmet patient needs.
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 1/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
Exscientia plc Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$4.70 |
| 52 Week High | US$9.12 |
| 52 Week Low | US$3.86 |
| Beta | 1.05 |
| 1 Month Change | 10.59% |
| 3 Month Change | -31.29% |
| 1 Year Change | -41.76% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -82.66% |
Recent News & Updates
Recent updates
Exscientia: Drug Discovery Platform Attracting Partners And Cash
May 22Exscientia: A Strategic Hold In The AI-Driven Drug Discovery Sector (Rating Downgrade)
Feb 26Is Exscientia (NASDAQ:EXAI) In A Good Position To Invest In Growth?
Jan 11
Earnings Update: Exscientia plc (NASDAQ:EXAI) Just Reported Its Third-Quarter Results And Analysts Are Updating Their Forecasts
Nov 12New Forecasts: Here's What Analysts Think The Future Holds For Exscientia plc (NASDAQ:EXAI)
Aug 31We're Keeping An Eye On Exscientia's (NASDAQ:EXAI) Cash Burn Rate
Aug 25Broker Revenue Forecasts For Exscientia plc (NASDAQ:EXAI) Are Surging Higher
Jul 21Exscientia (NASDAQ:EXAI) Is In A Good Position To Deliver On Growth Plans
Apr 22We're Not Very Worried About Exscientia's (NASDAQ:EXAI) Cash Burn Rate
Dec 30The Exscientia plc (NASDAQ:EXAI) Analysts Have Been Trimming Their Sales Forecasts
Aug 31Exscientia: Using AI To Power Drug Development
Aug 15Companies Like Exscientia (NASDAQ:EXAI) Can Afford To Invest In Growth
May 29Exscientia: Drug Discovery Using AI For Sanofi And Self-Owned Pipeline
Apr 12Bullish: Analysts Just Made A Sizeable Upgrade To Their Exscientia plc (NASDAQ:EXAI) Forecasts
Jan 09Shareholder Returns
| EXAI | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -8.4% | 0.7% | 1.2% |
| 1Y | -41.8% | 5.0% | 27.7% |
Return vs Industry: EXAI underperformed the US Biotechs industry which returned 5% over the past year.
Return vs Market: EXAI underperformed the US Market which returned 27.7% over the past year.
Price Volatility
| EXAI volatility | |
|---|---|
| EXAI Average Weekly Movement | 11.5% |
| Biotechs Industry Average Movement | 11.2% |
| Market Average Movement | 5.9% |
| 10% most volatile stocks in US Market | 16.2% |
| 10% least volatile stocks in US Market | 2.8% |
Stable Share Price: EXAI's share price has been volatile over the past 3 months.
Volatility Over Time: EXAI's weekly volatility (12%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2012 | 483 | Dave Hallett | www.exscientia.ai |
Exscientia plc, an artificial intelligence (AI) driven Pharma-tech company, engages in design and develop differentiated medicines for diseases with high unmet patient needs. The company’s lead product candidate GTAEXS617, a CDK7 inhibitor, which is currently in a Phase 1/2 trial to manage the potential toxicities associated with CDK7 as well as optimizing pharmacokinetics for maximizing on-target efficacy. It is also involved in the development of EXS4318, a PKC-theta inhibitor, under Phase 1 clinical trial for inflammation and immunology indications; EXS74539, a LSD1 inhibitor, under preclinical studies for SCLC, AML, and potential additional indications; EXS73565, a MALT1 inhibitor, under preclinical studies for multiple hematology indications; and DSP-0038, currently in Phase 1 studies.
Exscientia plc Fundamentals Summary
| EXAI fundamental statistics | |
|---|---|
| Market cap | US$593.96m |
| Earnings (TTM) | -US$163.35m |
| Revenue (TTM) | US$24.76m |
24.0x
P/S Ratio-3.6x
P/E RatioIs EXAI overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| EXAI income statement (TTM) | |
|---|---|
| Revenue | US$24.76m |
| Cost of Revenue | US$33.31m |
| Gross Profit | -US$8.55m |
| Other Expenses | US$154.80m |
| Earnings | -US$163.35m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.29 |
| Gross Margin | -34.53% |
| Net Profit Margin | -659.74% |
| Debt/Equity Ratio | 0.09% |
How did EXAI perform over the long term?
See historical performance and comparison